Engflag

Sazo 500

Quick links to important sections

Sazo 500

Sazo 500_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sazo 500

Property Description
Active ingredient Sulphasalazine (Sulfasalazine)
Form Oral Tablet (often enteric-coated)
Pharmacological class Disease-Modifying Anti-Rheumatic Drug (DMARD), 5-Aminosalicylate Derivative
Common use Managing chronic inflammation (e.g., in joints and intestines)
Origin Synthetic organic compound

What Type of Medicine is Sazo 500 (Sulphasalazine)?

Sazo 500 is a prescription-only synthetic organic compound whose active ingredient, Sulphasalazine (INN), is clinically recognized as a Disease-Modifying Anti-Rheumatic Drug (DMARD) and an Aminosalicylate Derivative. This classification signifies that the medicine is used not merely for temporary symptomatic pain relief but is intended to fundamentally influence the underlying course of chronic inflammatory diseases. The product is administered as an oral tablet, a standard presentation for DMARDs, and is widely acknowledged for its role as an anti-inflammatory agent in long-term disease management.

Composition and Unique Prodrug Structure

The single active ingredient is Sulphasalazine, which is chemically structured as a codrug—a combination of two pharmacologically relevant parts: 5-Aminosalicylic Acid (5-ASA) and the Sulfapyridine component. This unique structure ensures the drug functions as a prodrug; it is largely unabsorbed until it reaches the large intestine. The tablet is often enteric-coated, providing necessary physical protection to ensure the molecule travels intact, thereby allowing for the targeted release and subsequent delivery of the active component to the inflammatory site.

General Purpose of Sulphasalazine (Sazo 500)

The general purpose of Sulphasalazine is to achieve sustained disease control over chronic conditions by mitigating the effects of immune-driven inflammation and regulating immune activity. This mechanism is particularly beneficial in chronic conditions that feature persistent inflammation. By suppressing the processes that drive disease progression, Sulphasalazine offers a long-term disease-modifying effect, contributing significantly to the sustained management of the inflammatory state and the reduction of symptomatic flares.

What side effects are possible with Sazo 500?

Possible Side Effects and Safety Information

Regulatory documents classify the potential effects of Sulphasalazine (Sazo 500) based on their frequency and impact on body systems. The official safety profile is defined by common, expected reactions and the documentation of rare, serious adverse events.

Frequency-Classified Adverse Reactions

The most frequently documented adverse reactions, classified as Very Common in regulatory labeling, include headache, dizziness, and gastrointestinal disturbances such as nausea, abdominal pain, and dyspepsia. Reactions categorized as Common include leucopenia (decreased white blood cell count), diarrhea, vomiting, and generalized effects like fever and skin rash.

Serious Adverse Reactions and Systemic Safety

Rare, but clinically significant risks are documented, particularly concerning the Blood and Lymphatic System Disorders. These serious adverse reactions include Agranulocytosis, Aplastic Anemia, and Haemolytic Anemia. Severe, systemic skin reactions are also documented, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The labeling indicates potential for hepatotoxicity (liver damage) and interference with folic acid metabolism.

Time-Related Patterns and Restrictions

Certain effects are tied to exposure patterns. Blood dyscrasias and severe hypersensitivity reactions may occur early in treatment, often within the first few months. Reversible oligospermia (decreased sperm count) is associated with long-term exposure and typically resolves upon discontinuation. The medication is contraindicated in individuals with severe hepatic or renal impairment, porphyria, or known hypersensitivity to sulfonamides or salicylates. These restrictions define the specific safety limitations of the drug.

Overdose and Emergency Response

Suspected overdosage of Sazo 500 requires immediate professional medical intervention. Officially documented acute manifestations include gastrointestinal distress, such as nausea, vomiting, gastric distress, and abdominal pains, alongside central nervous system effects, including drowsiness and convulsions. The severity of toxicity is directly related to the measurable concentration of total sulfapyridine in the serum, which is a key parameter monitored during recovery.

Severe toxicity is associated with serious outcomes, including blood dyscrasias like agranulocytosis and aplastic anemia, as well as potential liver and renal damage. Patients must seek urgent medical attention immediately if they observe early signs of a severe systemic reaction, such as fever, jaundice, sore throat, or unexplained lymph node swelling.

Management procedures described in regulatory sources aim to remove unabsorbed drug and support systemic function. These measures include gastric lavage or emesis, catharsis, and specific fluid management: alkalinizing the urine and forcing fluids when kidney function is normal, or restricting fluids and salt if anuria is present. The label notes that specialized procedures, such as ureter catheterization, may be indicated for complete renal blockage caused by drug crystals.

Therapeutic Uses of Sazo 500

What Sazo 500 treats: main uses and benefits

Sazo 500 contains sulfasalazine, a compound that combines an antibacterial agent with an anti-inflammatory agent. It is primarily used to manage chronic inflammatory conditions affecting the joints and the digestive tract.

Inflammatory Bowel Disease (IBD)

Sazo 500 is frequently prescribed for the management of inflammatory bowel diseases. Its primary functions in this context include:

  • Ulcerative Colitis: It is used to treat active flares of ulcerative colitis and to help maintain periods of remission. The medication works locally within the colon to reduce swelling and redness in the intestinal lining.
  • Crohn's Disease: In certain cases, it may be used to manage symptoms of Crohn’s disease, particularly when the condition affects the large intestine.

Rheumatoid Arthritis

For patients with rheumatoid arthritis, Sazo 500 acts as a Disease-Modifying Anti-Rheumatic Drug (DMARD). Unlike standard pain relievers, it aims to address the underlying inflammatory process rather than just the symptoms. Benefits include:

  • Reduction of Joint Damage: By suppressing the overactive immune response, it helps slow the progression of joint destruction.
  • Symptom Management: It is used to decrease joint pain, swelling, and morning stiffness, improving overall physical function over time.

Other Inflammatory Conditions

In some clinical scenarios, Sazo 500 may be utilized for other forms of inflammatory arthritis, such as:

  • Ankylosing Spondylitis: Helping to manage inflammation in the spine and joints.
  • Psoriatic Arthritis: Addressing the joint inflammation associated with psoriasis.
  • Juvenile Idiopathic Arthritis: Used in pediatric populations when other treatments have not been sufficiently effective in controlling systemic inflammation.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Sazo 500? — Official Regulatory Information

The eligibility for Sazo 500 (Sulfasalazine) is strictly defined by regulatory documents, which classify certain populations and conditions as either contraindicated or requiring special consideration.

Populations for Whom Use is Contraindicated

Use of Sazo 500 is formally prohibited in individuals who have:

  • Hypersensitivity or Allergy to sulfasalazine, its metabolites, sulfonamides, or salicylates.
  • Intestinal or Urinary Obstruction (blockage).
  • Porphyria, a group of rare genetic disorders, as sulfonamides may precipitate an acute attack.

Populations Requiring Critical Appraisal or Special Consideration

The drug should only be given after critical appraisal by a healthcare provider to patients with pre-existing hepatic damage, renal damage, or blood dyscrasias (e.g., agranulocytosis). Use also requires caution in those with severe allergies or bronchial asthma.

Population / Condition Official Eligibility Status
Children under 2 years old Contraindicated (Safety and efficacy not established)
Children 6 years and older Use is generally established for specific indications
Pregnancy Category B (Animal studies revealed no evidence of harm to the fetus)
Lactation Drug and its metabolites pass into breast milk

Men taking Sazo 500 have reported oligospermia and temporary infertility; however, withdrawal of the medication appears to reverse these effects.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Sazo 500

Property Description
Medicinal product categories with documented interactions Thiopurines, highly protein-bound medicinal products, oral hypoglycemic agents, oral anticoagulants, antibiotics (affecting bowel flora), anion-exchange resins, hepatotoxic agents, and certain live vaccines (e.g., Live Typhoid Vaccine).
Specific interacting medicines (if explicitly listed) Methenamine, Digoxin, Methotrexate, Cyclosporine, Cholestyramine, Colestipol, Iron, and Folic Acid.
Mechanistic basis of interactions (only if stated in label) Inhibition of thiopurine methyltransferase (TPMT); competition for protein binding; binding by anion-exchange resins; inhibition of folic acid absorption and metabolism; and impairment of bacterial prodrug splitting (by antibiotics).
Timing-based interaction rules (if applicable) Co-administration with the live typhoid vaccine requires a minimum separation interval of at least 24 hours due to the potential for decreased immunological response.
Population-specific interaction notes (if applicable) Slow acetylator phenotype is associated with a greater likelihood of adverse reactions related to the metabolite Sulfapyridine, which impacts overall tolerability of co-administered agents.
Interaction-related restrictions Formally contraindicated for co-administration with Methenamine due to the risk of crystalluria. Co-administration with Azathioprine or 6-Mercaptopurine carries a documented risk of severe bone marrow suppression.
Interaction classifications (high-level) Interaction severity classification (as defined in official documents): Contraindicated (Methenamine); Use with Caution/Monitoring Required (Thiopurines, Digoxin, Oral Anticoagulants).

Official Interaction Statements:

  • The regulatory label explicitly lists Methenamine as a contraindicated combination due to crystalluria risk.
  • Co-administration with Azathioprine or 6-Mercaptopurine is associated with severe bone marrow suppression due to the documented inhibition of TPMT.
  • Sulphasalazine significantly reduces the absorption of Digoxin, potentially leading to non-therapeutic serum levels, and formally inhibits the absorption of Folic Acid.
  • It may potentiate the hypoglycaemic effect of oral hypoglycemic agents and impair the hepatic metabolism of oral anticoagulants.
  • The efficacy may be reduced by broad-spectrum antibiotics (e.g., Neomycin) that interfere with the bacterial cleavage of the prodrug in the bowel.

Connection to the overall interaction profile

Regulatory documents define the product’s interaction structure through official constraints, including explicit prohibitions and required monitoring for exposure modification or toxicity potentiation. The profile is characterized by several documented pharmacokinetic interactions involving impaired absorption, reduced clearance through protein-binding competition, and enzyme inhibition. The need for a minimum 24-hour separation from the live typhoid vaccine is a specific, mandated timing condition.

Mechanism of Action

How Sazo 500 Works

Sazo 500 (Sulphasalazine) functions as a prodrug that requires enzymatic breakdown to become active. Its unique mechanism relies on the azoreductase enzyme produced by colonic bacteria to cleave the molecule into two active moieties: 5-Aminosalicylic Acid (5-ASA) and Sulfapyridine (SP).

Inhibition of Inflammatory Signaling Enzymes

The 5-ASA component, largely unabsorbed, exerts its primary action locally by serving as an inhibitor of key enzymes in the Arachidonic Acid cascade, specifically Cyclooxygenase and 5-Lipoxygenase. This interaction reduces the synthesis of Prostaglandins and Leukotrienes (such as LTB4), thereby modulating local pathway activity.

Systemic Immunomodulation via Gene Control

The absorbed Sulfapyridine component mediates the systemic effect, engaging mechanisms that modify gene expression. This includes inhibition of the Nuclear Factor-kappa B ( NF-kappa B) transcription factor, which reduces the transcription of genes responsible for creating pro-inflammatory Cytokines ( TNF-alpha, IL-6). This upstream regulatory action contributes to the modulation of the chronic, self-perpetuating immune signaling process.

Dosage and Administration Information

How to Use Sazo 500

Sazo 500 tablets are a formulation of sulfasalazine and must be taken strictly according to the official instructions for use to ensure proper drug delivery and consistency of treatment.

Administration and Procedural Rules

  • Swallow the tablet whole with a full glass of water. Do not crush, break, or chew the tablet. This is a mandatory step to maintain the integrity of the delayed-release coating.
  • Fluid Intake: Patients must maintain adequate fluid intake throughout the day to prevent the risk of kidney-related issues.
  • Timing: The daily dosage must be taken in evenly divided doses, preferably after meals, with the interval between doses not exceeding eight hours.
  • Missed Dose: If a dose is missed, take it as soon as it is remembered. If it is nearly time for the next scheduled dose, skip the missed dose and return to the regular schedule. Do not take a double dose to compensate.

Official Dosing Rules (Adults and Children ≥ 6 years)

Condition Initial Dosing Maintenance Dosing
Ulcerative Colitis 3 to 4 grams per day, in evenly divided doses 2 grams per day, in evenly divided doses
Rheumatoid Arthritis 0.5 to 1 gram per day, in 1-2 divided doses (gradually increased weekly) Typically 2 grams per day, in 2 evenly divided doses

For children aged six years and older, dosing is determined by body weight, and the medicine is generally not recommended for use in children under two years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Chronic Pain and Musculoskeletal Conditions

Clinical research has assessed outcomes related to quality of life and the presentation of chronic pain in patients with musculoskeletal disorders. Studies examined the impact on disorders such as osteoarthritis, rheumatoid arthritis, and chronic low back pain.

  • One study specifically evaluated its potential role in outcomes related to neuropathic pain associated with damaged nerve tissue.
  • The evaluation suggested a potential for relief.
  • Participants in the study reported observations of change during the initial treatment period.

Tolerability and Long-Term Use

Studies also examined the tolerability of the combination for long-term use, and findings explored pain-related outcomes and tolerability, with findings comparing its reported side effect profile to traditional NSAIDs in the study population.

  • Trials included study populations of older adults, including those who may need alternatives to high-dose opioids.
  • While some individuals in the studies reported mild nausea or fatigue, trials evaluated the effect of different conditions of intake on these reported experiences. It is not yet clear whether this adjustment impacts the incidence of side effects.

Efficacy in Chronic Low Back Pain (CLBP)

A major focus of the research was the application of the combination therapy for Chronic Low Back Pain (CLBP).

  • In a large Randomized Controlled Trial (RCT), the trial explored the outcomes for chronic low back pain, documenting a positive response based on trial outcome measures in 85% of subjects.
  • Comparative trial results were documented between the combination therapy and single-drug treatment in this specific study.

Conclusion of Available Evidence

The available evidence summarizes the scope of investigation across various chronic pain conditions. However, further research is ongoing to fully establish the long-term profile and outcomes across broader patient populations.

Key Studies & References

  1. Clinical Guideline for the Management of Rheumatoid Arthritis in Older Adults

Frequently Asked Questions (FAQ)

Common questions about Sazo 500 (FAQ)

Q: How quickly do people usually start to notice any effects of Sazo 500?

A: Sazo 500 is a disease-modifying medicine, and its effects are typically not immediate. Official sources and clinical context indicate that some individuals may begin to notice changes after six to eight weeks. The full therapeutic effect is generally observed after up to three months of consistent use.

Q: What is the typical time frame for the full effect of Sazo 500 to be seen?

A: As a disease-modifying agent intended for long-term conditions, the full benefits of Sazo 500 can take time to develop. The maximum therapeutic effect is typically not fully realized until up to three months after starting the medicine, which is a common expectation for this class of drug.

Q: Is Sazo 500 known to interact with common pain relievers like ibuprofen?

A: Yes, official information indicates that Sulfasalazine may interact with non-steroidal anti-inflammatory drugs (NSAIDs), a class that includes ibuprofen. This is because both medications can potentially affect the kidneys and increase the risk of related problems. Concerns about specific interactions are best addressed by a healthcare provider.

Q: Can Sazo 500 be taken with vitamins or dietary supplements?

A: Regulatory information notes that Sazo 500 is known to interfere with the absorption of essential nutrients, specifically folic acid and iron. Reviewing all vitamins, supplements, and herbal remedies with a healthcare provider is a standard consideration due to the potential for interactions or nutrient deficiencies.

Q: Why do official documents mention the need for [specific lab test] while using Sazo 500?

A: Official documents require regular monitoring tests to check for serious, documented risks. This includes frequent complete blood counts (to check for blood disorders like agranulocytosis) and liver function tests (to check for liver damage). Regulatory documents indicate that this monitoring is frequently carried out during the initial phase of treatment.

Q: Does Sazo 500 affect energy levels?

A: While the impact on general 'energy levels' is not universally classified in official documents, common side effects can include headache and dizziness, which may affect how a person feels. Separately, some individuals have reported experiencing unusual tiredness or fatigue during treatment.

Q: Why might a person need to stop using Sazo 500 suddenly?

A: Immediate discontinuation of Sazo 500 is required if serious symptoms arise. This can include the onset of a fever, severe rash, jaundice, or a persistent sore throat, as these may be signs of a serious blood disorder or a severe hypersensitivity reaction.

Q: Are there specific symptoms that require immediate medical attention while using Sazo 500?

A: Symptoms that may warrant immediate medical attention include jaundice (yellowing of skin or eyes), purpura (blood spots on skin), pallor (unusual paleness), a persistent fever, or a sore throat. These symptoms may suggest a serious blood disorder or a severe hypersensitivity reaction.

Q: Do people report feeling better right after starting Sazo 500?

A: Sazo 500 is classified as a disease-modifying agent designed for long-term sustained control of chronic inflammatory conditions. Because of this mechanism, effects are typically not noticed right away, and a person should not expect immediate relief after starting the medication.

Q: What is the general duration of treatment described in official sources?

A: Official sources describe the use of Sazo 500 as maintenance therapy intended for chronic, long-term conditions like Ulcerative Colitis and Rheumatoid Arthritis. This classification implies continuous, ongoing use for sustained disease control over an extended period under medical supervision.

Q: What kind of monitoring is typically mentioned in official information for Sazo 500?

A: Regulatory information specifies the need for regular monitoring to manage potential risks. This typically involves checking complete blood counts (with differential white cell counts) and liver function tests. Official information indicates these tests are frequently conducted during the initial phase of treatment.

Q: Is Sazo 500 generally described as a well-tolerated medicine?

A: Official documents classify several reactions as very common, including headache, nausea, abdominal pain, and indigestion. Tolerability is often dose-dependent, and some studies examined its side-effect profile in comparison to other drug classes.

Q: Do the side effects of Sazo 500 usually go away over time?

A: Clinical experience suggests that common side effects, such as nausea and general malaise, often lessen or improve after the initial adjustment period. Furthermore, official information notes that the potential temporary decrease in sperm count (oligospermia) is generally reversible upon stopping the drug.

Q: Does Sazo 500 interact with birth control pills?

A: Information derived from regulatory and medical sources suggests that Sulfasalazine may reduce the effectiveness of oral contraceptives that contain estrogen. This potential interaction may increase the risk of an unintended pregnancy or cause breakthrough bleeding.

Q: Does Sazo 500 contain lactose or gluten?

A: Official product labeling lists the inactive ingredients used in the tablet's formulation. However, specific information regarding the presence of common excipients like lactose or gluten can vary by manufacturer and specific product and is often not explicitly stated in core regulatory documents.

Q: What is the connection between Sazo 500 and sun sensitivity?

A: Regulatory documents indicate that Sulfasalazine may cause a reaction known as photosensitivity, which is an increased sensitivity of the skin to sunlight. Because of this, official recommendations often include the use of sunscreen and protective clothing during sun exposure.

Q: Does Sazo 500 affect sleep patterns?

A: While not listed as a common or very common side effect in all regulatory sources, patient reports have occasionally mentioned experiencing changes in sleep patterns, such as insomnia or poor sleep, while using the medication.

Q: Is Sazo 500 known to cause problems with concentration?

A: Official safety data lists central nervous system effects such as headache and dizziness as very common. Some patient reports have also noted related side effects, such as brain fog or difficulty with concentration.

Q: Are there known interactions between Sazo 500 and alcohol?

A: The official guidelines typically state that there is no specific prohibition against consuming alcohol while taking the medication. However, because Sazo 500 can cause stomach upset and has the potential to affect the liver, alcohol consumption could potentially worsen these particular side effects.

How should Sazo 500 be stored and disposed of?

How to Store and Dispose of Sazo 500?

Sazo 500 (sulfasalazine) tablets must be stored according to official regulatory requirements to maintain product stability.

Required Storage Conditions

Condition Type Requirement
Temperature Store at Controlled Room Temperature, 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F).
Protection Keep from freezing, excess heat, and direct light. Store away from moisture.
Container Keep in the container it came in, and ensure it is tightly closed.
Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Do not use the medicine past its expiration date or keep outdated product. To discard unused or expired Sazo 500, patients must ask a healthcare professional or pharmacist for specific instructions regarding pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sazo 500 found in:

A-Z Index: